NCT04836182Phase 2Completed

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-10-19Actual
Enrollment · participants72Actual
Source updated2023-09-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.